Skip to content
Basket0
Basket

Your basket is empty.

Your basket is empty.

view_cart
☰

Nootropil

Nootropil
In stock
400mg · 800mg
from A$51.94
Strength
Pack size — the bigger the pack, the cheaper the tablet
A$62.33A$51.94
A$1.73 per tablet

In brief

  • In our pharmacy, you can buy nootropil without a prescription, with delivery across Australia and discreet packaging.
  • Nootropil is a branded formulation of piracetam used mainly for cortical myoclonus and, in some countries, for cognitive impairment, vertigo and balance disorders; it acts as a nootropic by modulating neuronal function and cerebral microcirculation and supporting cerebral metabolism.
  • The usual dose varies by indication: tablets are commonly 800 mg or 1,200 mg; typical adult daily doses are approximately 2.4–4.8 g divided into two or three doses (higher doses may be used under specialist supervision); oral solutions are 200 mg/ml or 333 mg/ml and parenteral solutions are 200 mg/ml, dosed as directed by a clinician.
  • Forms of administration include oral film‑coated tablets, oral solution (200 mg/ml and 333 mg/ml), and solution for injection/infusion (200 mg/ml).
  • Onset time: blood levels rise within 1–2 hours; some symptomatic effects may be noticed within hours to days, but clinical benefits for cognition or balance can take several days to weeks.
  • Duration of action: elimination half‑life is about 4–5 hours in adults, so effects typically last several hours and dosing is commonly repeated 2–3 times daily.
  • Alcohol warning: avoid alcohol while taking nootropil as it may increase side effects and impair cognition; consult your healthcare professional if unsure.
  • The most common side effect is headache.
  • Would you like to try nootropil without a prescription?

Basic Nootropil Information

  • INN (International Nonproprietary Name): piracetam
  • Brand Names Available In Australia: not specified
  • ATC Code: N06BX03 – piracetam
  • Forms & Dosages: film‑coated tablets 800 mg and 1200 mg; oral solutions 200 mg/ml and 333.3 mg/ml; parenteral solution 200 mg/ml (product presentations vary by market).
  • Manufacturers In Australia: not specified
  • Registration Status In Australia: not specified
  • OTC / Rx Classification: not specified

Critical Warnings And Restrictions

Before prescribing or supplying Nootropil (piracetam) confirm the medicine’s regulatory and prescription status with the treating clinician and the local pharmacist.

Nootropil is a branded formulation of piracetam used mainly for cortical myoclonus and, in some countries, for cognitive and balance disorders.

National authorisations for piracetam vary, so always check the Australian Register of Therapeutic Goods (ARTG) and local prescribing rules before supply.

  • Contraindications: known hypersensitivity to piracetam or any excipient.
  • Use Caution Or Contraindicate: severe renal impairment until renal function and dosing are reviewed by the prescriber.
  • Bleeding Risk: observe for increased bleeding if patients are on antiplatelet or anticoagulant therapy and consult the prescriber.

When considering off‑label use document informed consent and a clear monitoring plan.

In overdose, refer patients to the local Poisons Information Centre immediately.

High‑Risk Groups

  • Elderly patients — monitor falls risk, renal function and drug interactions.
  • Pregnant or breastfeeding people — exercise caution; specialist advice recommended.
  • Children — authorised paediatric use varies by country; do not extrapolate adult dosing without specialist guidance.
  • People with significant hepatic or renal disease — check baseline function and arrange periodic monitoring.

Monitoring schedule (brief):

  • Baseline renal function (eGFR) before starting long‑term therapy.
  • Repeat renal function 1–3 months after initiation, then periodically depending on age and comorbidity.
  • Review bleeding signs and concomitant anticoagulant therapy at each visit.

Interaction With Activities

Patients performing safety‑critical work must be counselled about possible dizziness, drowsiness or coordination changes.

Advise avoidance of driving or heavy machinery until the individual response to therapy is known and documented.

Q&A — Can I Drive After Taking It In Australia?

Short answer: Do not drive if you experience dizziness, drowsiness, confusion or impaired coordination after taking piracetam.

  • Do not drive while symptomatic.
  • Report any new dizziness, blurred vision or confusion to your prescriber.
  • Document the driving advice in the patient record.

Usage Basics: INN, Brand Names, Legal Classification

What is this medicine and how is it identified?

INN
piracetam
Brand Names
Nootropil (originator historically UCB Pharma; some markets use ADVANZ Pharma).
Therapeutic Class
Nootropic / psychostimulant‑like agent that modulates neuronal function and microcirculation.
ATC
N06BX03

Actions for pharmacists when an overseas prescription arrives:

  • Verify prescriber identity and prescription authenticity.
  • Confirm the intended indication with the prescriber.
  • Inform the prescriber about local regulatory status and any need for Special Access pathways.
  • Check renal dosing and need for monitoring.

Dosing Guide

Which strengths and forms should pharmacists expect to see?

Documented Nootropil presentations include film‑coated tablets (800 mg, 1200 mg), oral solutions (200 mg/ml and 333.3 mg/ml) and parenteral solution 200 mg/ml in some markets.

Standard adult dosing varies by indication and country, and higher divided daily doses are often used for cortical myoclonus.

Examples — confirm with the prescriber:

  • Tablet options: 800 mg or 1200 mg film‑coated tablets; doses are commonly divided across the day for tolerability.
  • Oral solution: labelled as 200 mg/ml or 333.3 mg/ml for flexible dosing where used.
  • Parenteral: 200 mg/ml ampoules for IV/IM use in specific hospital settings in some countries.
Formulation Example Conversion
800 mg tablet 1 tablet = 800 mg piracetam
1200 mg tablet 1 tablet = 1200 mg piracetam
200 mg/ml oral solution 1 ml = 200 mg piracetam
333.3 mg/ml oral solution 1 ml = 333.3 mg piracetam
200 mg/ml injection 1 ml = 200 mg piracetam

Checklist before dispensing:

  • Confirm patient weight where paediatric dosing is relevant.
  • Check baseline renal function if long‑term treatment is planned.
  • Review concomitant medicines and pregnancy/breastfeeding status.

Q&A — What If I Miss A Dose?

Take the missed dose as soon as you remember unless it is close to the next scheduled dose.

Do not double the dose to make up for missed doses.

Contact the prescriber if several consecutive doses are missed or if you are unsure about the schedule.

Interaction Chart

Food and drink interactions to discuss with patients.

  • Avoid alcohol until individual tolerance is known because alcohol can worsen dizziness and cognitive effects.
  • Caffeine may increase subjective stimulation; counsel on combined effects if the patient uses high caffeine beverages.
Concomitant Agent / Class Risk / Advice
Anticoagulants / Antiplatelets Potential for increased bleeding risk; liaise with prescriber and monitor bleeding signs.
Antiepileptic Drugs May be used adjunctively for myoclonus; check for dosing adjustments and clinical response.
Diuretics Consider effects on renal handling and hydration status; check renal function.
SSRIs / Other Neuroactive Agents Monitor for additive central effects such as dizziness or agitation.
NSAIDs Monitor for bleeding if combined with antiplatelet therapy.

Critical checks at dispensing:

  • Warfarin or DOAC use.
  • Current antiepileptic regimen.
  • Concomitant antiplatelet agents or NSAIDs.
  • Nephrotoxic agents and recent renal function tests.
Major
Significant bleeding risk with anticoagulant/antiplatelet combinations — consult prescriber.
Moderate
Possible additive CNS effects with other neuroactive drugs; counsel accordingly.
Minor
Food interactions mainly relate to alcohol and caffeine — advise on moderation.

User Reports And Trends

What are Australian patients saying?

Consumer sentiment is anecdotal and biased by self‑selection, but common themes emerge from forums and pharmacy consultations.

  • Positive: some report perceived improvements in concentration or clarity in specific situations.
  • Neutral: many report no noticeable change, especially when used for non‑authorised cognitive enhancement.
  • Negative: complaints about headache, gastrointestinal upset or expense; concerns about product authenticity for imported supplies.

Advice for pharmacists when patients report effects:

  • Encourage reporting of suspected adverse events to the TGA adverse event reporting system.
  • Discuss experiences with the prescriber rather than adjusting doses without medical advice.
  • Log outcomes: efficacy, side effects, adherence, and source of supply.

Access And Purchase Options

Typical Australian supply routes include community pharmacies, hospital pharmacies, specialist clinics and online pharmacies or telehealth services.

Ensure prescription validity and check ARTG/PBS status before supply.

  • If Nootropil/piracetam is not registered locally, clinicians may require Special Access Scheme (SAS) applications or authorised prescriber arrangements.
  • When filling an overseas prescription validate the prescriber, check dose and formulation, counsel the patient and advise on regulatory status.

Note on availability: in our online pharmacy, nootropil is available without a prescription, with discreet delivery to Australia in 9-21 days.

Supply differences — rural versus urban:

  • Rural: potential stock shortages and longer freight times.
  • Urban: better access to specialist clinics and faster delivery from local pharmacies.

Mechanism And Pharmacology

How does piracetam work in plain language?

Piracetam is classified as a nootropic that modulates neuronal function and may improve cerebral microcirculation and metabolic support to brain tissue.

Nootropic
An agent that may influence cognitive function, attention or memory processes.
ATC Code
N06BX03 — piracetam.
Pharmacokinetics
Oral absorption with systemic distribution; elimination is predominantly renal so renal dosing adjustments may be necessary in impaired function.

Clinical implications:

  • Piracetam can be helpful in cortical myoclonus as part of combination therapy in countries where authorised.
  • Evidence for general cognitive enhancement is variable and indication‑dependent.
  • Monitor renal function when using long term due to renal clearance considerations.

Indications And Off‑Label Uses

What is Nootropil authorised for internationally and what about Australian practice?

International Authorised Indications Typical Australian Practice / Status Recommended Clinical Action
Adult cortical myoclonus (several EU countries, UK SmPC) Check local TGA/ARTG status; not uniformly authorised in Australia Use under specialist supervision; document indication and consent
Psycho‑organic syndromes, vertigo, adjunctive dyslexia treatment (example: Romania) Often off‑label in Australia Consider only after literature review and informed consent; monitor outcomes
General cognitive enhancement Generally off‑label and not routinely recommended Prefer evidence‑based alternatives and non‑pharmacological options

Checklist for clinicians considering off‑label prescribing:

  • Perform a targeted literature review for the indication.
  • Obtain informed consent and document rationale.
  • Agree measurable goals and a monitoring plan before initiation.

Key Clinical Findings

Summarised evidence and clinical implications.

  • Strong evidence exists for piracetam in the treatment of cortical myoclonus in countries where it is authorised.
  • Evidence for cognitive benefits in dementia, post‑stroke cognitive impairment or dyslexia is mixed and varies by study quality and population.
  • Clinical trials and meta‑analyses show heterogeneity in dosing, formulations and endpoints which complicates extrapolation to routine practice.
Indication Study Design Main Finding Clinical Implication
Cortical Myoclonus Controlled studies in specialist centres Improvement in myoclonic control as adjunctive therapy Use under specialist supervision; monitor seizure control
Cognitive Disorders Mixed RCTs and observational studies Inconsistent benefits; results vary by population Consider alternatives with stronger evidence for dementia

Clinicians should consult up‑to‑date databases such as Cochrane and PubMed before off‑label use.

Alternatives Matrix

Compare piracetam with PBS‑listed alternatives used in similar clinical contexts.

Drug PBS Status Indication Mechanism Pros / Cons
Antiepileptics (eg. sodium valproate) Listed for epilepsy indications Myoclonus / seizure control Modulate neuronal excitability Pros: evidence for seizure control. Cons: side effect profile; monitor bloods.
Cholinesterase Inhibitors (eg. donepezil) PBS listed for Alzheimer’s dementia Dementia cognitive symptoms Increase cholinergic transmission Pros: PBS subsidy and evidence for AD. Cons: GI side effects; not for general enhancement.
Betahistine PBS status varies Vertigo and balance disorders Vestibular function modulation Pros: commonly used for vertigo. Cons: limited evidence in some populations.

Pros and cons checklist when choosing an alternative:

  • Prefer PBS‑listed options when evidence and subsidy are available.
  • Consider safety and monitoring burden, particularly renal or hepatic monitoring.
  • Use non‑pharmacological interventions first for cognitive enhancement: sleep, exercise and vascular risk reduction.

Common Questions

Short, practical answers to frequent pharmacy queries.

  • Is it legal in Australia? Check ARTG and TGA pathways; registration is country‑dependent.
  • Can I buy it over the counter? This depends on local classification and product registration; verify before supply.
  • What are common side effects? Headache, gastrointestinal upset, agitation and dizziness are commonly reported.
  • How soon will I notice an effect? Time to perceived benefit varies by indication and patient; for myoclonus clinical evaluation guides response assessment.
  • Is it safe with my other medications? Always perform medication reconciliation and consult the prescriber for interactions with anticoagulants or neuroactive drugs.

Micro‑FAQ — Will It Improve My Memory?

Limited and inconsistent evidence supports piracetam as a general memory enhancer; specialist assessment is advised before use for cognitive enhancement.

Pharmacists should document counselling and report adverse events to the TGA when suspected.

Price And Access Comparison

Source Likely Price Range (AUD) PBS Subsidy Status Prescription Required Notes On Authenticity / Regulation
Community Pharmacy Varies by supplier Depends on ARTG/PBS listing Usually yes Preferred verified supply route
Private Import Often higher due to freight and import fees No May require SAS or prescriber documentation Check batch and MAH details carefully
Online Overseas Retailers Variable; sometimes cheaper but risky No May not require prescription on seller site Higher risk of counterfeit or mislabelled products
Hospital Supply Generally not charged to patient in admitted setting Institutional procurement Prescriber orders only Used for inpatient or specialist care

Checklist for patients considering imports:

  • Confirm ARTG listing or SAS approval before ordering.
  • Request batch numbers, manufacturer details and original labelling.
  • Keep receipts and product packaging and consult a pharmacist on arrival.

Registration And Regulation

Australian regulatory pathways to know.

ARTG
Australian Register of Therapeutic Goods — check current registration status.
PBS
Pharmaceutical Benefits Scheme — listing determines subsidy availability.
SAS
Special Access Scheme — pathway for unregistered medicines on a case‑by‑case basis.
Authorised Prescriber
Allows a clinician to prescribe an unregistered medicine to a defined patient group under approval.

Pharmacist checklist when presented with an overseas prescription:

  • Confirm lawful importation and check documentation.
  • Request prescriber justification and monitor for safety concerns.
  • Counsel the patient on legal and safety implications and consider contacting the TGA for complex queries.

Storage And Handling

Practical advice for household and pharmacy storage.

Tablets and oral solutions are generally stored at controlled room temperature and protected from moisture and direct sunlight.

In Australian climates be mindful of heat and humidity and advise storage in a cool cabinet away from bathrooms.

Setting Recommended Condition
Household Original container, dry place, out of reach of children, avoid high heat
Pharmacy Store per product leaflet; observe temperature ranges and avoid excessive humidity
Parenteral Forms Follow cold‑chain SOPs if required; do not freeze
After Opening (Oral Solutions) Follow product leaflet for expiry after opening

Dispose of unused medicines via local pharmacy take‑back services rather than household rubbish.

Guidelines For Proper Use And Pharmacist Counselling

Practical step‑by‑step counselling for pharmacists.

  1. Verify the indication and prescriber details before dispensing.
  2. Confirm ARTG/PBS status and advise the prescriber if special access is required.
  3. Review allergies, pregnancy/breastfeeding status, renal function and bleeding risk.
  4. Provide a clear dosing schedule and missed‑dose advice.
  5. Advise about common side effects and when to seek urgent care.
  6. Document counselling and arrange a follow‑up plan with the prescriber.

Script template for a short counselling interaction:

  • Purpose: “This medicine, Nootropil (piracetam), is prescribed for [indication].”
  • Expected benefit: “We will look for improvements in [specific measurable goal].”
  • Side effects: “Common effects can include headache, nausea and dizziness; stop and seek help for serious bleeding or severe allergic reaction.”
  • Storage and follow up: “Store in the original container, check renal function as advised, and return for review in [timeframe].”

Encourage reporting of adverse events to the TGA and submission of safety or effectiveness observations to specialist registries when applicable.

Delivery Across Australia

City Region Delivery time
Sydney New South Wales 9-14 days
Melbourne Victoria 9-14 days
Brisbane Queensland 9-14 days
Perth Western Australia 9-14 days
Adelaide South Australia 9-14 days
Canberra Australian Capital Territory 9-14 days
Hobart Tasmania 9-14 days
Darwin Northern Territory 9-14 days
Gold Coast Queensland 9-14 days
Newcastle New South Wales 9-14 days
Wollongong New South Wales 9-14 days
Geelong Victoria 9-14 days
Townsville Queensland 14-21 days
Cairns Queensland 14-21 days

Related products